OPKO Health, Inc. (0KCS.L)
| Chiusura precedente | 1,9400 |
| Aperto | 1,9400 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 1,9200 - 1,9400 |
| Intervallo di 52 settimane | 1,9200 - 1,9400 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 9,102M |
| Beta (5 anni mensile) | 1,75 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,1790 |
| Prossima data utili | 26 ott 2022 - 31 ott 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Jon Cohen and Michael Hansen Join Talkspace’s Board of Directors
Shareholders Approve All Measures at First Annual Meeting of StockholdersNEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (Nasdaq: TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company’s board of directors and approved all other shareholder proposals during the company’s first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Healt
- GlobeNewswire
OPKO Health Announces Leadership Changes for BioReference Laboratories
MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced that Jon R. Cohen, M.D., is retiring from his role as Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President and a Director of OPKO. He will remain as an employed advisor to the company through the end of December 2022 and continue as a consultant for the following nine months to assist in positioning t
- GlobeNewswire
OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Aug. 04, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2022. Business highlights for the second quarter of 2022 and subsequent weeks include the following: Acquired ModeX Therapeutics, Inc. (ModeX), gained proprietary immunotherapy technology, seasoned scientific team, new executives and Directors. ModeX is focused on developing uni
